Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,503.45
(
-1.56%
)
US TECH 100
23,272.00
(
-1.89%
)
Dow Jones
45,540.44
(
-1.05%
)
Brent Oil
108.46
(
3.85%
)
Bitcoin
69,879.53
(
-0.03%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tarado96 post# 3173

Tuesday, 04/03/2007 9:58:45 PM

Tuesday, April 03, 2007 9:58:45 PM

Post# of 19309
In addition to timeline info, the ReadMeFirst contains these entries for the U.S. Atryn trial:

#msg-6543884 Limited availability of competing antithrombin
#msg-5607789 Efficacy endpoint is clinical DVT
#msg-5609005 Design of control arm
#msg-11410659 Likelihood of success
#msg-6632420 Patient eligibility and exclusions
#msg-11511614 Musings on a U.S. partnership

Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today